Print

The impact of palbociclib (Ibrance) on overall survival for metastatic breast cancer patients in the PALOMA-3 trial

https://www.facingourrisk.org/XRAY/palbociclib-overall-survival-metastatic-breast-cancer
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1810527

The PALOMA-3 clinical trial showed that a new CDK4/6 inhibitor in combination therapy improved progression-free survival of women treated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women with prior disease progression after endocrine therapy. This XRAYS reviews a newly published study in the New England Journal of Medicine that looks at overall survival in the original PALOMA-3 study. (1/23/19)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following studies look at treatment for people with metastatic ER-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 

 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.